(Q85960573)
Statements
Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration (English)
Brandon G Busbee
Allen C Ho
David M Brown
Jeffrey S Heier
Ivan J Suñer
Zhengrong Li
Roman G Rubio
Phillip Lai
HARBOR Study Group
23 January 2013